Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14551866 | 0.83 | CHRNB2 (0.43) | CHRNB2CHRNA4MAPTKMT2A | |
| SCHEMBL7054960 | 0.74 | — | — | |
| SCHEMBL1507066 | 0.74 | — | — | |
| SCHEMBL3050102 | 0.73 | CHRNB2 (0.70) | CHRNB2CHRNA4 | |
| SCHEMBL1863295 | 0.73 | CYP1A1 (0.48) | CHRNB2CHRNA4 | |
| SCHEMBL768929 | 0.73 | ATM (0.38) | CHRNB2CHRNA4 | |
| SCHEMBL1865390 | 0.73 | HCAR2 (0.38) | — | |
| SCHEMBL177674 | 0.72 | TSHR (0.47) | MAPT | |
| SCHEMBL12086548 | 0.71 | CHRNB2 (0.44) | CHRNB2CHRNA4 | |
| SCHEMBL12086547 | 0.71 | CHRNB2 (0.44) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120019049-A | Azole modulators of cholesterol biosynthesis and their use for promoting remyelination | 基因泰克公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119707930-A | Aromatic ring compound and its prepn and use | 甘李药业股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-114555604-B | Pharmaceutical compounds | 辉瑞公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118679170-A | Nitrogen-containing heterocyclic compound, and preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-113166177-B | Boron-containing PDE4 inhibitors | 辉瑞公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-118339145-A | Bicyclic fused ring derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-07-12 | — | — | CN | disclosed |
| CN-117940424-A | EGFR inhibitors | 缆图药品公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117510472-A | Uracil derivative having virus proliferation inhibitory activity and pharmaceutical composition containing same | 盐野义制药株式会社 | 2024-02-06 | — | — | CN | disclosed |
| CN-117203195-A | Uracil derivative having virus proliferation inhibitory activity and pharmaceutical composition containing same | 盐野义制药株式会社 | 2023-12-08 | — | — | CN | disclosed |
| CN-116848107-A | Compounds and their use as PDE4 activators | 米罗尼德有限公司 | 2023-10-03 | — | — | CN | disclosed |
| US-8865911-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2014-10-21 | — | — | US | disclosed |
| WO-2014066659-A1 | HETEROARYL INHIBITORS OF PDE4 | TETRA DISCOVERY PARTNERS, LLC. (US) | 2014-05-01 | — | — | WO | disclosed |
| EP-2655378-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | AstraZeneca AB (SE) | 2013-10-30 | — | — | EP | disclosed |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | ASTRAZENECA INTELLECTUAL PROPERTY | 2013-08-15 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012087237-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
| WO-2012040641-A2 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2011130741-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | BACE1, BACE2, APP | CHRNB2 37/4885CHRNA4 170/4885MAPT 6/4885 |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | BACE1, BACE2, APP | CHRNB2 37/4885CHRNA4 170/4885MAPT 6/4885 |
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | CHRNB2 34/4885CHRNA4 184/4885MAPT 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.